Clinical Advances of Molecular-targeted Therapy on Primary Hepatocellular Carcinoma

Primary hepatocellular carcinoma is one of major causes of death worldwide. Although advanced treatment methods have been developed recently,such as surgical resection,liver transplantation,local ablation,transcatheter arterial chemoembolization,radiotherapy,systemic chemotherapy,etc.,it is still showed very low clinical efficacies with very low 5-years survival rate. Over the past 10 years,as the investigation advances in basic research of hepatocellular carcinoma,as well as the development of signal transduction pathway of hepatocellular carcinoma becomes more clear,the molecular targeted drugs for hepatocellular carcinoma,represented by Sorafenib,are increasingly valued in clinic and used in the treatment of advanced hepatocellular carcinoma widely. In addition,the survival time of patients with advanced hepatocellular carcinoma has been prolonged and the qualities of life have been improved. In this article,the progress and applications of molecular targeted therapy of hepatocellular carcinoma have been reviewed.